Elutia Inc

Q2 total net sales were $2.4 million versus $2.7 million in the prior-year period, and first-half 2026 net sales were $5.5 million versus $5.7 million a year ago. GAAP gross margin was 59.6% versus 52.9% last year, and adjusted gross margin was 70.7% versus 62.7%, up 8 percentage points year over year. Total operating expenses were $9.4 million versus $9.8 million, loss from operations improved to $8 million from $8.4 million, net loss was $7.6 million versus $9.6 million, and adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million. Management did not give formal next-quarter revenue guidance, but said it expects the company to be funded through at least 2028, with NXT-41 clearance in Q4 2026, NXT-41x clearance in the first half of 2027, a soft launch in the second half of 2027, and full commercial launch in 2028.

Randy Mills framed the quarter around three strategic priorities: funding the business, narrowing the company’s focus, and validating demand for NXT-41x. He emphasized that Elutia is now concentrating on reconstruction and believes the capital, divestitures, regulatory progress, and manufacturing readiness position the company for the product’s launch cycle. His tone was confident and very product-focused, especially around the surgeon survey and the belief that NXT-41x addresses a large, unresolved clinical problem.

Matthew Ferguson said the quarter’s financials reflected lower sales, but better gross margin and tighter operating expenses. He highlighted that the company ended Q2 with $19.9 million in cash and expects up to an additional $34 million from signed transactions and facility availability, bringing total cash sources to $54 million. He also noted that R&D rose by $1.5 million to support NXT-41/41x, while net litigation costs fell by $1.9 million, and said the funding should provide runway through at least 2028.

Analysts focused on FDA timing, manufacturing capacity, the shape of the planned soft launch, and the post-divestiture expense run rate. Management said the FDA meeting was meant to ensure responses to agency questions on NXT-41 were fully responsive and said the team came away feeling very good about the path forward. On manufacturing, management said launch capacity should support at least $300 million of revenue and that scaling beyond that would mainly require more personnel and shifts, not new facilities or equipment. On the soft launch, they said the key will be building hospital value analysis committee support before the 2028 full launch.